Abstract | PURPOSE:
NK105 is a new drug delivery system formulation for paclitaxel (PTX) whose recommended dose (RD) is 150 mg PTX equivalent/m(2) administered every 3 weeks, as determined in a phase I trial. This study aimed to evaluate the efficacy and safety of NK105 in patients with advanced gastric cancer after failure of first-line chemotherapy. EXPERIMENTAL DESIGN: Eligible patients had measurable disease and one chemotherapeutic regimen except taxane. NK105 (150 mg PTX equivalent/m(2)) was administered by a 30-minute intravenous infusion every 3 weeks without anti-allergic premedication until disease progression, unacceptable toxicity or patient refusal. The primary efficacy endpoint was best overall response rate (ORR) post baseline. The secondary endpoints were progression-free survival (PFS), time to treatment failure (TTF) and overall survival (OS). All adverse events were reported using CTCAE v3.0. RESULTS: Between November 2007 and July 2009, 57 patients were enrolled and 56 were evaluable for efficacy. Two complete responses and 12 partial responses were observed for an ORR of 25%. The median PFS was 3.0 months, the median TTF was 2.8 months, and the median OS was 14.4 months. Drug related toxicity was mainly mild (grades 1-2) to severe (grades 3-4); other data: neutropenia (64.9%); leukopenia (17.5%); lymphopenia (8.8%); neuropathy-sensory (1.8%); fatigue (3.5%); and stomatitis (1.8%). There were no treatment-related deaths. CONCLUSIONS: This study of NK105 (150 mg PTX equivalent/m(2)) proves the concept for the modest activity and tolerability of a new drug delivery system formulation for PTX. A phase III trial will be evaluated to clarify survival benefit.
|
Authors | Ken Kato, Keisho Chin, Takaki Yoshikawa, Kensei Yamaguchi, Yasushi Tsuji, Taito Esaki, Kenji Sakai, Masami Kimura, Tetsuya Hamaguchi, Yasuhiro Shimada, Yasuhiro Matsumura, Ryuji Ikeda |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 30
Issue 4
Pg. 1621-7
(Aug 2012)
ISSN: 1573-0646 [Electronic] United States |
PMID | 21728023
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Micelles
- NK105
- Paclitaxel
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, pharmacokinetics, therapeutic use)
- Demography
- Disease-Free Survival
- Female
- Humans
- Male
- Micelles
- Middle Aged
- Nanoparticles
(chemistry)
- Neoplasm Recurrence, Local
(drug therapy, pathology)
- Neoplasm Staging
- Paclitaxel
(adverse effects, analogs & derivatives, pharmacokinetics, therapeutic use)
- Stomach Neoplasms
(drug therapy, pathology)
- Time Factors
- Treatment Outcome
|